Ignite Creation Date:
2024-05-06 @ 7:02 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05870475
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2023-04-10
Brief Title:
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistantIntolerant PV
Sponsor:
Institute of Hematology Blood Diseases Hospital China
Organization:
Institute of Hematology Blood Diseases Hospital China
Organization Data
Organization:
Institute of Hematology Blood Diseases Hospital China
Class:
OTHER
Study ID:
IIT2023018
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Institute of Hematology Blood Diseases Hospital China
Lead Sponsor Class:
OTHER
Responsible Party:
Zhang Lei MD
Responsible Party Title:
ProfessorVice director of Thrombosis Hemostasis Center
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Institute of Hematology Blood Diseases Hospital China
Old Name:
None
Old Organization:
None